European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2023 update
M Rouprêt, T Seisen, AJ Birtle, O Capoun… - European urology, 2023 - Elsevier
Abstract Context The European Association of Urology (EAU) guidelines panel on upper
urinary tract urothelial carcinoma (UTUC) has updated the guidelines to aid clinicians in …
urinary tract urothelial carcinoma (UTUC) has updated the guidelines to aid clinicians in …
Bladder cancer
L Dyrskjøt, DE Hansel, JA Efstathiou… - Nature Reviews …, 2023 - nature.com
Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …
[HTML][HTML] Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma
MS Van Der Heijden, G Sonpavde… - … England Journal of …, 2023 - Mass Medical Soc
Background No new agent has improved overall survival in patients with unresectable or
metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy …
metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy …
Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer
T Powles, BP Valderrama, S Gupta… - … England Journal of …, 2024 - Mass Medical Soc
Background No treatment has surpassed platinum-based chemotherapy in improving
overall survival in patients with previously untreated locally advanced or metastatic …
overall survival in patients with previously untreated locally advanced or metastatic …
Rational combinations of targeted cancer therapies: background, advances and challenges
H Jin, L Wang, R Bernards - Nature Reviews Drug Discovery, 2023 - nature.com
Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
Combination strategies to maximize the benefits of cancer immunotherapy
S Zhu, T Zhang, L Zheng, H Liu, W Song, D Liu… - Journal of hematology & …, 2021 - Springer
Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
T Powles, J Bellmunt, E Comperat… - Annals of …, 2022 - annalsofoncology.org
Urothelial carcinoma (UC), also described as bladder cancer, is the 10th most common
cancer type worldwide, with an estimated 549 000 new cases and 200 000 deaths in 2018 …
cancer type worldwide, with an estimated 549 000 new cases and 200 000 deaths in 2018 …
DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy
R Huang, PK Zhou - Signal transduction and targeted therapy, 2021 - nature.com
Genomic instability is the hallmark of various cancers with the increasing accumulation of
DNA damage. The application of radiotherapy and chemotherapy in cancer treatment is …
DNA damage. The application of radiotherapy and chemotherapy in cancer treatment is …
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised …
T Powles, T Csőszi, M Özgüroğlu, N Matsubara… - The Lancet …, 2021 - thelancet.com
Summary Background PD-1 and PD-L1 inhibitors are active in metastatic urothelial
carcinoma, but positive randomised data supporting their use as a first-line treatment are …
carcinoma, but positive randomised data supporting their use as a first-line treatment are …